Clearmind Medicine Doses 20 Participants in CMND-100 AUD Trial, Advances to Higher Dose Cohort
CMND is trading near its 52-week low of $0.52 (0.2% below the low) on light trading volume (0.1× avg).
Summary
Clearmind Medicine announced it has treated 20 participants in its ongoing Phase I/IIa clinical trial for CMND-100, an investigational treatment for Alcohol Use Disorder. This update follows the successful dosing of two additional participants in the fourth cohort, which features a higher dose of 160 mg, based on a positive Data and Safety Monitoring Board (DSMB) recommendation. The company previously reported 18 participants had completed treatment and follow-up. The consistent favorable safety and tolerability data observed across all cohorts is a crucial positive signal for this early-stage drug. For a micro-cap biotech company, continued progress and positive safety data in a clinical trial are highly material, de-risking the development pathway. Investors will now watch for further updates on the trial's progression and any preliminary efficacy signals.
At the time of this announcement, CMND was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.52 to $52.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.